In this context, inhibiting SPL, by implication restoring the reduced sphingolipid metabolites may be a new approach to managing ME/CFS, which warrants future investigation. This evidence concerns the gene SGPL1 and myalgic encephalomeyelitis/chronic fatigue syndrome.